Overview Dividends

(NNNN) Anbio Biotechnology - Ratings and Ratios

Exchange: NASDAQ • Country: Germany • Currency: USD • Type: Common Stock • ISIN: KYG0367B1059

Antigen Tests, Immunoassay, Amplification, Polymerase Chain Reaction

EPS (Earnings per Share)

EPS Growth (3y CAGR): -100.00%
EPS Trend (3y Corr): -100.0%

Qual. Beats: 0

Revenue

Revenue Growth (3y CAGR): -30.07%
Revenue Trend (3y Corr): -10.4%

Qual. Beats: 0

Risk via 10d forecast
Volatility	124%
Value at Risk 5%th	188%
Relative Tail Risk	-8.05%

Reward TTM
Sharpe Ratio	2.03
Alpha	354.40

Character TTM
Hurst Exponent	0.456
Beta	0.297
Beta Downside	0.992

Drawdowns 3y
Max DD	76.41%
Mean DD	16.29%
Median DD	9.15%

Description: NNNN Anbio Biotechnology November 10, 2025

Anbio Biotechnology (NASDAQ: NNNN) is a German-based, publicly traded firm that develops and markets in-vitro diagnostics (IVD) products across the EU, Asia-Pacific, North America, South America, Africa and other regions. Its portfolio includes SARS-CoV-2 antigen rapid tests, combined SARS-CoV-2/Influenza A/B rapid tests, and a range of assay platforms such as lateral-flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification (LAMP), chemiluminescence immunoassay (CLIA) and RT-PCR. The company serves over-the-counter (OTC), point-of-care (POC) and central laboratory markets, and was incorporated in 2021 with headquarters in Frankfurt am Main, Germany.

Key industry context that could affect Anbio’s outlook: (1) The global IVD market is projected to grow at a ~6 % compound annual growth rate through 2029, driven by aging populations and expanding molecular testing adoption. (2) The European Union’s IVDR (In-Vitro Diagnostic Regulation) implementation raises compliance costs but also creates higher entry barriers, potentially benefiting incumbents with certified product lines. (3) Post-pandemic demand for multiplex respiratory panels remains elevated, giving companies that can bundle COVID-19 and flu testing a pricing premium; however, publicly disclosed revenue and cash-burn figures for NNNN are limited, so the firm’s current financial runway is uncertain.

If you want a data-rich, side-by-side comparison of NNNN’s financial metrics, valuation multiples and peer performance, the ValueRay platform provides a consolidated view that can help you gauge the stock’s risk-adjusted upside.

NNNN Stock Overview

Market Cap in USD	2,316m
Sub-Industry	Biotechnology
IPO / Inception	2025-02-19
Return 12m vs S&P 500	329%
Analyst Rating	-

NNNN Dividends

Currently no dividends paid

NNNN Growth Ratios

Metric	Value
CAGR 3y	651.06%
CAGR/Max DD Calmar Ratio	8.52
CAGR/Mean DD Pain Ratio	39.97
Current Volume	8.2k
Average Volume	23.6k

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (5.00m TTM) > 0 and > 6% of Revenue (6% = 966.5k TTM)

FCFTA 0.17 (>2.0%) and ΔFCFTA 10.60pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 104.3% (prev 186.7%; Δ -82.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.17 (>3.0%) and CFO 3.22m <= Net Income 5.00m (YES >=105%, WARN >=100%)

Net Debt (-11.8m) to EBITDA (5.01m) ratio: -2.35 <= 3.0 (WARN <= 3.5)

Current Ratio 10.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (42.3m) change vs 12m ago NaN% (target <= -2.0% for YES)

Gross Margin 62.07% (prev 50.07%; Δ 12.00pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 97.98% (prev 48.09%; Δ 49.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -11.23 (EBITDA TTM 5.01m / Interest Expense TTM -408.6k) >= 6 (WARN >= 3)

Altman Z'' 21.09

(A) 0.89 = (Total Current Assets 18.5m - Total Current Liabilities 1.73m) / Total Assets 18.9m

(B) 0.91 = Retained Earnings (Balance) 17.2m / Total Assets 18.9m

warn (B) unusual magnitude: 0.91 — check mapping/units

(D) 9.93 = Book Value of Equity 17.2m / Total Liabilities 1.73m

Total Rating: 21.09 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.80

1. Piotroski 5.0pt

2. FCF Yield 0.14%

3. FCF Margin 20.01%

4. Debt/Equity data missing

5. Debt/Ebitda -2.35

6. ROIC - WACC (= 21.35)%

7. RoE 30.99%

8. Rev. Trend -10.36%

9. EPS Trend -100.0%

What is the price of NNNN shares?

As of November 21, 2025, the stock is trading at USD 26.60 with a total of 8,241 shares traded.
Over the past week, the price has changed by +14.11%, over one month by -11.89%, over three months by -47.38% and over the past year by +361.01%.

Is NNNN a buy, sell or hold?

Anbio Biotechnology has no consensus analysts rating.

What are the forecasts/targets for the NNNN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	-	-
Analysts Target Price	-	-
ValueRay Target Price	26.6	-0.2%

NNNN Fundamental Data Overview November 19, 2025

Market Cap USD = 2.32b (2.32b USD * 1.0 USD.USD)
P/E Trailing = 858.3334
P/S = 276.1584
P/B = 119.9687
Beta = None
Revenue TTM = 16.1m USD
EBIT TTM = 4.59m USD
EBITDA TTM = 5.01m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -11.8m USD (from netDebt column, last quarter)
Enterprise Value = 2.30b USD (2.32b + (null Debt) - CCE 11.8m)
Interest Coverage Ratio = -11.23 (Ebit TTM 4.59m / Interest Expense TTM -408.6k)
FCF Yield = 0.14% (FCF TTM 3.22m / Enterprise Value 2.30b)
FCF Margin = 20.01% (FCF TTM 3.22m / Revenue TTM 16.1m)
Net Margin = 31.03% (Net Income TTM 5.00m / Revenue TTM 16.1m)
Gross Margin = 62.07% ((Revenue TTM 16.1m - Cost of Revenue TTM 6.11m) / Revenue TTM)
Gross Margin QoQ = 84.55% (prev 66.85%)
Tobins Q-Ratio = 121.8 (set to none) (Enterprise Value 2.30b / Total Assets 18.9m)
Interest Expense / Debt = unknown (Interest Expense -408.6k / Debt none)
Taxrate = 0.0% (0.0 / 2.37m)
NOPAT = 4.59m (EBIT 4.59m * (1 - 0.00%))
Current Ratio = 10.71 (Total Current Assets 18.5m / Total Current Liabilities 1.73m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = -2.35 (Net Debt -11.8m / EBITDA 5.01m)
Debt / FCF = -3.65 (Net Debt -11.8m / FCF TTM 3.22m)
Total Stockholder Equity = 16.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 26.42% (Net Income 5.00m / Total Assets 18.9m)
RoE = 30.99% (Net Income TTM 5.00m / Total Stockholder Equity 16.1m)
RoCE = 26.70% (EBIT 4.59m / Capital Employed (Total Assets 18.9m - Current Liab 1.73m))
RoIC = 28.46% (NOPAT 4.59m / Invested Capital 16.1m)
WACC = 7.11% (E(2.32b)/V(2.32b) * Re(7.11%) + (debt-free company))
Discount Rate = 7.11% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈2.29m ; Y1≈2.83m ; Y5≈4.83m
Fair Price DCF = 1.87 (DCF Value 82.1m / Shares Outstanding 43.9m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -100.0 | EPS CAGR: -100.00% | SUE: N/A | # QB: 0
Revenue Correlation: -10.36 | Revenue CAGR: -30.07% | SUE: N/A | # QB: 0

Additional Sources for NNNN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle